News on Medial

IXP unveils Rs 200 Cr early-stage fund for lifesciences startups

Entrackr · 11d

IXP, a Life Sciences VC backed by JV Ventures, has announced the launch of its first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from pre-seed to Series A stages. The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 200 crore, with a greenshoe option of Rs 100 crore. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Life Sciences sector, the fund will invest in innovations across areas such as pharma, biotechnology, medical technology, specialty chemicals, agrotechnology, and nutraceuticals. Through IXP Venture Studio, it will co-create companies alongside scientists to develop ideas that address unmet market needs. Unlike traditional VCs, it takes a hands-on approach, actively participating from concept to scale. The Venturepreneur Program has been designed to transform scientists into founders. According to IXP, early-stage companies require access to larger ecosystems, including laboratories, networks, and R&D services, which it provides through PoweRx, the Life Sciences vertical of JV Ventures. The VC firm leverages synergies within the group to create a winning proposition for portfolio companies. IXP (Innovation Acceleration Platform) aims to support scientists and innovators in their entrepreneurial journey by integrating them into a rich life sciences ecosystem. The VC firm emphasizes that it is built by a strong team and understands the capital-intensive nature and long gestation periods associated with R&D, helping bring innovative ideas to market.